Επιστημονικές Δημοσιεύσεις

Σε Διεθνή περιοδικά

  1. Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D, Montorsi F, Vardi Y, Wespes E. Guidelines on Male Sexual Dysfunction: Erectile Dysfunction and Premature Ejaculation. Eur Urol. 2010; 57:804 – 814.
  2. Hatzichristou D, Rosen RC, Derogatis LR, Low WY, Meuleman EJ, Sadovsky R, Symonds T. Recommendations for the clinical evaluation of men and women with sexual dysfunction. J Sex Med. 2010;7(1 Pt 2):337-48.
  3. Apostolidis A, Kirana PS, Chiu G, Link C, Tsiouprou M, Hatzichristou D. Gender and Age Differences in the Perception of Bother and Health Care Seeking for Lower Urinary Tract Symptoms: Results from the Hospitalised and Outpatients' Profile and Expectations Study. Eur Urol. 2009; 56(6): 937 – 947.
  4. Kirana PS, Papaharitou S, Athanasiadis L, Nakopoulou E, Salpiggidis G, Moysidis K, Pipilaki C, Hatzimouratidis K, Tzotstzis V, Portseli A, Iraklidou M, Apostolidis A, Bekos A, Hatzichristou D. A conceptual framework for the evolution of sexual medicine and a model for the development of alternative sexual health services: 10-years experience of the Centre for Sexual and Reproductive Health. J Sex Med. 2009 Sep;6(9):2405-16.
  5. Hatzimouratidis K, Hatzichristou DG. Phosphodiesterase type 5 inhibitors: unmet needs. Curr Pharm Des. 2009;15(30):3476-85.
  6. Kirana PS, Rosen R, Hatzichristou D. Subjective well- being as a determinant of individuals’ responses to symptoms: Development of a biopsychosocial conceptual framework. Int J Clin Pract. 2009 Oct;63(10):1435-45.
  7. Nakopoulou E, Kirana PS, Chiu G, Link C, Rosen R, Hatzichristou D. Level of bother and treatment seeking predictors among male and female in-patients with sexual problems: A hospital-based study. J Sex Med. 2009 Nov 24.
  8. Nakopoulou E, Papaharitou S, Hatzichristou D. Patients' sexual health: a qualitative research approach on Greek nurses' perceptions. J Sex Med. 2009 Aug;6(8):2124-32.
  9. Hatzichristou D. Iñigo Sáenz de Tejada y Gorman - An aristocrat and pioneer in sexual medicine. Eur Urol. 2009 Jul;56(1):234-5.
  10. Hatzimouratidis K, Burnett AL, Hatzichristou D, McCullough AR, Montorsi F, Mulhall JP. Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application. Eur Urol. 2009 Feb;55(2):334-47.
  11. Buvat J, Hatzichristou D, Maggi M, Farmer I, Martínez-Jabaloyas JM, Miller PJ, Schnetzler G. Efficacy, tolerability and satisfaction with sildenafil citrate 100-mg titration compared with continued 50-mg dose treatment in men with erectile dysfunction. BJU Int. 2008 Dec;102(11):1645-50.
  12. Hatzichristou D. Understanding individuals' response to erectile dysfunction. Int J Impot Res. 2008 Dec;20 Suppl 2:S15-20.
  13. Hatzimouratidis K, Moysidis K, Bekos A, Giakoumelos A, Hatzichristou D. What is adequate management to preserve erectile function after unilateral nerve-sparing radical prostatectomy? J Endourol. 2008 Sep;22(9):2029-31.
  14. Papaharitou S, Nakopoulou E, Moraitou M, Tsimtsiou Z, Konstantinidou E, Hatzichristou D. Exploring sexual attitudes of students in health professions. J Sex Med. 2008 Jun;5(6):1308-16.
  15. Papaharitou S, Nakopoulou E, Kirana P, Giaglis G, Moraitou M, Hatzichristou D. Factors associated with sexuality in later life: An exploratory study in a group of Greek married older adults. Arch Gerontol Geriatr. 2008 Mar-Apr;46(2):191-201.
  16. Bekos A, Arvaniti M, Hatzimouratidis K, Moysidis K, Tzortzis V, Hatzichristou D. The natural history of Peyronie's disease: an ultrasonography-based study. Eur Urol. 2008 Mar;53(3):644-50.
  17. Ferenidou F, Kapoteli V, Moisidis K, Koutsogiannis I, Giakoumelos A, Hatzichristou D. Presence of a sexual problem may not affect women's satisfaction from their sexual function. J Sex Med. 2008 Mar;5(3):631-9.
  18. Hatzichristou D, Gambla M, Rubio-Aurioles E, Buvat J, Brock GB, Spera G, Rose L, Lording D, Liang S. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. Diabet Med. 2008 Feb;25(2):138-46.
  19. Hatzimouratidis K, Hatzichristou DG. Looking to the future for erectile dysfunction therapies. Drugs. 2008;68(2):231-50.
  20. Kaplan SA, Hatzichristou D. Open to debate. The motion: PDE5 inhibitors will have a significant role in the treatment of BPH. Eur Urol. 2007 Nov;52(5):1523-7.
  21. Hatzichristou D, Haro JM, Martin-Morales A, von Keitz A, Riley A, Bertsch J, Belger M, Wolka AM, Beardsworth A; EDOS Group. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study. Int J Clin Pract. 2007 Nov;61(11):1850-62.
  22. Hatzimouratidis K, Hatzichristou D. Testosterone and erectile function: an unresolved enigma. Eur Urol. 2007 Jul;52(1):26-8.
  23. Papaharitou S, Nakopoulou E, Moraitou M, Hatzimouratidis K, Hatzichristou D. Reproductive health and midwives: does occupational status differentiate their attitudes on assisted reproduction technologies from those of the general population? Hum Reprod. 2007 Jul;22(7):2033-9.
  24. Hatzimouratidis K, Koliakos N, Koutsogiannis I, Moisidis K, Giakoumelos A, Hatzichristou D. Removal of a detached head of the Brooks dilator from the corpora cavernosa during penile prosthesis implantation. J Sex Med. 2007 Jul;4(4 Pt 2):1179-81.
  25. Mitropoulos D, Papakonstantinou E, Aletras AJ, Kalinderis N, Zervas A, Hatzichristou D, Karakiulakis G. Terazosin modifies the content of glycosaminoglycans and the activity of matrix metalloproteinase 2 in the rat ventral prostate. Eur Urol. 2007 Feb;51(2):447-56.
  26. Tsimtsiou Z, Kerasidou O, Efstathiou N, Papaharitou S, Hatzimouratidis K, Hatzichristou D. Medical students' attitudes toward patient-centred care: a longitudinal survey. Med Educ. 2007 Feb;41(2):146-53.
  27. Hatzimouratidis K, Hatzichristou D. Phosphodiesterase type 5 inhibitors: the day after. Eur Urol. 2007 Jan;51(1):75-88.
  28. Hatzimouratidis K, Hatzichristou D. Sexual dysfunctions: classifications and definitions.J Sex Med. 2007 Jan;4(1):241-50.
  29. Konstantinidou E, Apostolidis A, Kondelidis N, Tsimtsiou Z, Hatzichristou D, Ioannides E. Short-term efficacy of group pelvic floor training under intensive supervision versus unsupervised home training for female stress urinary incontinence: a randomized pilot study. Neurourol Urodyn. 2007;26(4):486-91.
  30. Porst H, Sharlip ID, Hatzichristou D, Rubio-Aurioles E, Gittelman M, Stancil BN, Smith PM, Wilkins HJ, Pommerville P; Vardenafil Study Group. Extended duration of efficacy of vardenafil when taken 8 hours before intercourse: a randomized, double-blind, placebo-controlled study. Eur Urol. 2006 Nov;50(5):1086-94
  31. McCullough AR, Carson CC, Hatzichristou D. A prospective study of the beneficial effects of dose optimization and customized instructions on patient satisfaction with sildenafil citrate (Viagra) for erectile dysfunction. Urology. 2006 Sep;68(3 Suppl):38-46.
  32. Hatzimouratidis K, Moysidis K, Bekos A, Tsimtsiou Z, Ioannidis E, Hatzichristou D. Treatment strategy for "non-responders" to tadalafil and vardenafil: a real-life study. Eur Urol. 2006 Jul;50(1):126-32.
  33. Broderick GA, Donatucci CF, Hatzichristou D, Torres LO, Valiquette L, Zhao Y, Loughney K, Sides GD, Ahuja S. Efficacy of tadalafil in men with erectile dysfunction naïve to phosphodiesterase 5 inhibitor therapy compared with prior responders to sildenafil citrate. J Sex Med. 2006 Jul;3(4):668-75.
  34. Tsimtsiou Z, Hatzimouratidis K, Nakopoulou E, Kyrana E, Salpigidis G, Hatzichristou D. Predictors of physicians' involvement in addressing sexual health issues. J Sex Med. 2006 Jul;3(4):583-8.
  35. Wespes E, Amar E, Hatzichristou D, Hatzimouratidis K, Montorsi F, Pryor J, Vardi Y. EAU Guidelines on erectile dysfunction: an update. Eur Urol. 2006 May;49(5):806-15.
  36. Haro JM, Beardsworth A, Casariego J, Gavart S, Hatzichristou D, Martin-Morales A, Schmitt H, Mirone V, Needs N, Riley A, Varanese L, von Keitz A, Kontodimas S. Treatment-seeking behavior of erectile dysfunction patients in Europe: Results of the Erectile Dysfunction Observational Study. J Sex Med. 2006 May;3(3):530-40.
  37. Mallis D, Moisidis K, Kirana PS, Papaharitou S, Simos G, Hatzichristou D. Moderate and severe erectile dysfunction equally affects life satisfaction. J Sex Med. 2006 May;3(3):442-9.
  38. Heaton JW, Hatzichristou D. Open to debate: there is a role for chronic treatment with PDE5-inhibitors. Eur Urol. 2006 Apr;49(4):749-53.
  39. Papaharitou S, Athanasiadis L, Nakopoulou E, Kirana P, Portseli A, Iraklidou M, Hatzimouratidis K, Hatzichristou D. Erectile dysfunction and premature ejaculation are the most frequently self-reported sexual concerns: profiles of 9,536 men calling a helpline. Eur Urol. 2006 Mar;49(3):557-63.
  40. Athanasiadis L, Papaharitou S, Salpiggidis G, Tsimtsiou Z, Nakopoulou E, Kirana PS, Moisidis K, Hatzichristou D. Educating physicians to treat erectile dysfunction patients: development and evaluation of a course on communication and management strategies. J Sex Med. 2006 Jan;3(1):47-55.
  41. Dean, J., de Boer, B.-J., Graziottin, A., Hatzichristou, D., Heaton, J., Tailor, A. Effective Erectile Dysfunction (ED) Treatment Enables Men to Enjoy Better Sex: The Importance of Erection Hardness, Psychological Well-Being, and Partner Satisfaction (2006) European Urology, Supplements, 5 (13), pp. 761-766.
  42. Dean, J., de Boer, B.-J., Graziottin, A., Hatzichristou, D., Heaton, J., Tailor, A. The Role of Erection Hardness in Determining Erectile Dysfunction (ED) Treatment Outcome (2006) European Urology, Supplements, 5 (13), pp. 767-772.
  43. Dean, J., de Boer, B.-J., Graziottin, A., Hatzichristou, D., Heaton, J., Tailor, A. Erectile Dysfunction and Sexual Satisfaction: New Perspectives (2006) European Urology, Supplements, 5 (13), pp. 759-760.
  44. Dean, J., de Boer, B.-J., Graziottin, A., Hatzichristou, D., Heaton, J., Tailor, A. Psychological, Social, and Behavioural Benefits for Men Following Effective Erectile Dysfunction (ED) Treatment: Men Who Enjoy Better Sex Experience Improved Psychological Well-Being (2006) European Urology, Supplements, 5 (13), pp. 773-778.
  45. Dean, J., de Boer, B.-J., Graziottin, A., Hatzichristou, D., Heaton, J., Tailor, A. Partner Satisfaction and Successful Treatment Outcomes for Men with Erectile Dysfunction (ED) (2006) European Urology, Supplements, 5 (13), pp. 779-785
  46. Hatzimouratidis K, Hatzichristou D. Vardenafil in the treatment of erectile dysfunction: a review of clinical data and personal clinical experience. Ageing Health, Dec 2005.
  47. Hatzimouratidis K, Hatzichristou DG. Pharmacological treatment of erectile dysfunction: a 2005 update. European Pharmacotherapy 2006, 2-8.
  48. Mallis D, Moysidis K, Nakopoulou E, Papaharitou S, Hatzimouratidis K, Hatzichristou D. Psychiatric morbidity is frequently undetected in patients with erectile dysfunction. J Urol 2005;174:1913-1916.
  49. Hatzichristou DG. Phosphodiesterase 5 Inhibitors and Nonarteritic Anterior Ischemic Optic Neuropathy (NAION): Coincidence or Causality? J Sex Med 2005;2:751–758.
  50. Hatzichristou DG, Aliotta P, Auerbach S, Barkin J, Lording D, Murdock M, Wilkins HJ, McBride T, Colopy MW, Carson CC for the PROVEN Study Group. Erectile response to vardenafil in men with a history of non-response to sildenafil: A time-from-dosing descriptive analysis. Clin Ther 2005; 27:1452-1461.
  51. Papaharitou S, Nakopoulou E, Kyrana PS, Iraklidou M, Athanasiadis L, Hatzichristou D. Women’s sexual concerns: data analysis from a help-line. J Sex Med, 2005; 2:652-657.
  52. Kostis, JB, Jackson, G, Rosen, R, Barrett-Connor, E, Billups, K, Burnett, AL, Carson, C, Cheitlin, M, DeBusk, R, Fonseca, V, Ganz, P, Goldstein, I, Guay, A, Hatzichristou, D, Hollander, JE, Hutter, A, Katz, S, Kloner, RA, Mittleman, M, Montorsi, F, Montorsi, P, Nehra, A, Sadovsky, R, Shabsigh, R. Sexual Dysfunction and Cardiac Risk:The 2nd Princeton Consensus Conference. Am J Cardiol, 2005; 96(2):313-21.
  53. Hatzimouratidis K, Hatzichristou D. A Comparative Review of the Options for Treatment of Erectile Dysfunction: Which Drug for Which Patient? Drugs; 65(12): 1621-1650, 2005.
  54. Hatzichristou DG, Vardi Y, Papp G, Pushkar D, Basson BR, Kopernicky V. Effect of Tadalafil (CialisTM) on Sexual Timing Behavioural Patterns in Men with Erectile Dysfunction: Integrated Analysis of Randomised, Placebo-Controlled Trials. J Urol.2005;174:1356-1359.
  55. Hatzichristou D, Apostolidis A, Bekos A, Tzortzis V, Ioannidis E, Yannakoyorgos K. Sildenafil failures may be due to inadequate instructions and follow-up: a study on 100 non-responders. Eur Urol, 2005; 47(4):518-22.
  56. Lue TF, Giuliano F, Montorsi F, Rosen R, Andersson KE, Althof S, Christ G, Hatzichristou D, Hirsch M, Kimoto Y, Lewis R, McKenna K, MacMahon C, Morales A, Mulcahy J, Padma-Nathan H, Pryor J, Saenz de Tejada I, Shabsigh R, Wagner G. Summary of the Recommendations on Sexual Dysfunctions in Men. . J Sex Med. 2004; 1(1): 6-23.
  57. Carson CC, Hatzichristou DG, Carrier S, Lording D, Lyngdorf P, Aliotta P, Auerbach S, Murdoch M, Azam U, McBride T,9 Colopy MW for the Patient Response With Vardenafil in Sildenafil Non-Responders (PROVEN) Study Group. Erectile response with vardenafil in sildenafil non-responders: a multicenter, double-blind, 12-week, flexible-dose, placebo-controlled erectile dysfunction clinical trial. BJU Int, 2004; 94; 1301-1309.
  58. Hatzichristou DG, Rosen R, Broderick G, Clayton A, Cuzin B, Derogatis L, Litwin M, Meuleman E, O’Leary M, Quirk F, Sadovsky R, Seftel A. Clinical Evaluation and Management Strategy of Sexual Dysfunction in Men and Women. J Sex Med. 2004; 1(1): 49-57.
  59. Hatzichristou DG, Cuzin B, Martin-Morales A, Buvat J, Porst H, Laferriere N, Bandel T.J, Montorsi F. Vardenafil Improves Satisfaction Rates, Depressive Symptomatology, and Self-Confidence in a Broad Population of Men with Erectile Dysfunction. J Sex Med. 2005; 2 (1), 109-116.
  60. Hatzichristou DG: Comments from Dimitrios Hatzichristou, Reviews and Education Editor. J Sex Med. 2004; 1(1): 3.
  61. Hatzimouratidis K, Hatzichristou DG. Treatment Options for Erectile Dysfunction in Patients Failing Oral DrugTherapy. EAU Update Series 2004, 2;75-83.
  62. Carson C, Giuliano F, Goldstein I, Hatzichristou D, Hellstrom W, Lue T, Montorsi F, Munarriz R, Nehra A, Porst H, Rosen R. The 'effectiveness' scale-therapeutic outcome of pharmacologic therapies for ED: an international consensus panel report. Int J Impot Res. 2004;16(3):207-13.
  63. Hatzichristou D, Montorsi F, Buvat J, Laferriere N, Bandel TJ, Porst H. The efficacy and safety of flexible-dose vardenafil (levitra) in a broad population of European men. Eur Urol. 2004 May;45(5):634-41.
  64. Kalyvas KD, Kotakidou R, Trantos A, Yannakoyorgos K, Hatzichristou DG. Paratesticular well-differentiated, adipocytic type liposarcoma presenting as inguinal hernia. Urol Int. 2004;72(3):264-8.
  65. Hatzichristou DG, Tzortzis V, Hatzimouratidis K, Apostolidis A, Moysidis K, Panteliou S. Protective role of the glans penis during coitus. Int J Impot Res. 2003 Oct;15(5):337-42.
  66. Hatzichristou DG, Hatzimouratidis K, Tzortzis V, Apostolidis A, Bekos A, Ioannidis E. Normal hemodynamic parameters do not always predict the presence of a rigid erection: a quantitative assessment of functional erectile impairment. Int J Impot Res. 2003 Apr;15(2):99-104.
  67. Stanopoulos I, Hatzichristou D, Tryfon S, Tzortzis V, Apostolidis A, Argyropoulou P. Effects of sildenafil on cardiopulmonary responses during stress. J Urol. 2003 Apr;169(4):1417-21. 
  68. Nehra A, Pryor J, Althof SE, Andersson K, Carson C, Giuliano F, Hatzichristou D, Hedlund H, Meuleman E, Montorsi F, Porst H, Riley A, Saenz de Tejada I, Stief C, Wespes E. Second International Conference on management of erectile dysfunction: new perspectives on treatment. Int J Impotence Res 2002, 14: S1-S5.
  69. Hatzichristou D, Salpiggidis G, Hatzimouratidis K, Apostolidis A, Tzortzis V, Bekos A, Saripoulos D. Management strategy for arterial priapism: therapeutic dilemmas. J Urol. 2002 Nov;168(5):2074-7.
  70. McCullough AR, Barada JH, Fawzy A, Guay AT, Hatzichristou D. Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology. 2002 Sep;60(2 Suppl 2):28-38.
  71. Hatzichristou D, Hatzimouratidis K, Bekas M, Apostolidis A, Tzortzis V, Yannakoyorgos K. Diagnostic steps in the evaluation of patients with erectile dysfunction. J Urol. 2002 Aug;168(2):615-20.
  72. Argyriou A, Hatzichristou DG. Recent advances in therapy for impotence. Hospital Prescriber Europe, 2002; 3:16-17.
  73. Wagner G, Claes H, Costa P, Cricelli C, De Boer J, Debruyne FM, Dean J, Dinsmore WW, Fitzpatrick JM, Ralph DJ, Hackett GI, Heaton JP, Hatzichristou DG, Mendive J, Meuleman EJ, Mirone V, Montorsi F, Raineri F, Schulman CC, Stief CG, Von Keitz AT, Wright PJ; Lygon Arms Group. A shared care approach to the management of erectile dysfunction in the community. Int J Impot Res. 2002 Jun;14(3):189-94.
  74. Hatzichristou DG, Hatzimouratidis K, Apostolidis A, Tzortzis V, Bekos A, Ioannidis E. Corporoplasty using tunica albuginea free grafts for penile curvature: surgical technique and long-term results. J Urol. 2002 Mar;167(3):1367-70.
  75. Wespes E, Amar E, Hatzichristou D, Montorsi F, Pryor J, Vardi Y; European Association of Urology Guidelines on erectile dysfunction. Eur Urol. 2002 Jan;41(1):1-5.
  76. Hatzichristou DG, Pescatori ES. Current treatments and emerging therapeutic approaches in male erectile dysfunction. BJU International 2001 Oct;88 Suppl 3:11-7.
  77. Hatzichristou DG. Sildenafil citrate: lessons learned from 3 years of clinical experience. Int J Impot Res. 2001 ;13 Suppl 6:S1-S10.
  78. Hatzichristou DG, Apostolidis A, Tzortzis V, Hatzimouratidis K, Kouvelas D. Effects of oral phentolamine, taken before sleep, on nocturnal erectile activity: a double-blind, placebo-controlled, crossover study. Int J Impot Res. 2001 Oct;13(5):303-8.
  79. Hatzichristou DG, Apostolidis A, Tzortzis V, Hatzimouratidis K, Ioannides E, Yannakoyorgos K. Glansectomy: an alternative surgical treatment for Buschke-Lowenstein tumors of the penis. Urology. 2001 May;57(5):966-9.
  80. Hatzichristou DG, Apostolidis A, Tzortzis V, Ioannides E, Yannakoyorgos K, Kalinderis A. Sildenafil versus intracavernous injection therapy: efficacy and preference in patients on intracavernous injection for more than 1 year. J Urol. 2000 Oct;164(4):1197-200.
  81. Goulas A, Papakonstantinou E, Karakiulakis G, Mirtsou-Fidani V, Kalinderis A, Hatzichristou DG. Tissue structure-specific distribution of glycosaminoglycans in the human penis. Int J Biochem Cell Biol. 2000 Sep;32(9):975-82.
  82. Goulas A, Hatzichristou DG, Karakiulakis G, Mirtsou-Fidani V, Kalinderis A, Papakonstantinou E. Benign hyperplasia of the human prostate is associated with tissue enrichment in chondroitin sulphate of wide size distribution. Prostate. 2000 Jul 1;44(2):104-10.
  83. Hatzichristou DG, Hatzimouratidis K, Apostolidis A, Ioannidis E, Yannakoyorgos K, Kalinderis A. Hemodynamic characterization of a functional erection. Arterial and corporeal veno-occlusive function in patients with a positive intracavernosal injection test. Eur Urol. 1999;36(1):60-7.
  84. Udelson D, Nehra A, Hatzichristou DG, Azadzoi K, Moreland RB, Krane RJ, Saenz de Tejada I, Goldstein I. Engineering analysis of penile hemodynamic and structural-dynamic relationships: Part III--Clinical considerations of penile hemodynamic and rigidity erectile responses. Int J Impot Res. 1998 Jun;10(2):89-99.
  85. Hatzichristou DG, Hatzimouratidis K, Ioannides E, Yannakoyorgos K, Dimitriadis G, Kalinderis A. Nocturnal penile tumescence and rigidity monitoring in young potent volunteers: reproducibility, evaluation criteria and the effect of sexual intercourse. J Urol. 1998 Jun;159(6):1921-6.
  86. Hatzichristou DG. Current treatment and future perspectives for erectile dysfunction. Int J Impot Res. 1998 May;10 Suppl 1:S3-13.
  87. Udelson D, Nehra A, Hatzichristou DG, Azadzoi K, Moreland RB, Krane RJ, Saenz de Tejada I, Goldstein I. Engineering analysis of penile hemodynamic and structural-dynamic relationships: Part II-Clinical implications of penile buckling. Int J Impot Res. 1998 Mar;10(1):25-35.
  88. Udelson D, Nehra A, Hatzichristou DG, Azadzoi K, Moreland RB, Krane J, Saenz de Tejada IS, Goldstein I. Engineering analysis of penile hemodynamic and structural-dynamic relationships: Part I--Clinical implications of penile tissue mechanical properties. Int J Impot Res. 1998 Mar;10(1):15-24.
  89. Hatzichristou DG. Management of voiding, bowel and sexual dysfunction in multiple sclerosis: towards a holistic approach. Sexuality and Disability, 14(1):3-7, 1996.
  90. Hatzichristou DG, Omata S, Constantinou CE. New method for direct stiffness measurement of the corpora cavernosa. Int J Impot Res. 1995 Dec;7(4):221-31.
  91. Hatzichristou DG, Saenz de Tejada I, Kupferman S, Namburi S, Pescatori ES, Udelson D, Goldstein I. In vivo assessment of trabecular smooth muscle tone, its application in pharmaco-cavernosometry and analysis of intracavernous pressure determinants. J Urol. 1995 Apr;153(4):1126-35.
  92. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Construction of a surrogate variable for impotence in the Massachusetts Male Aging Study. J Clin Epidemiol. 1994 May;47(5):457-67.
  93. Hatzichristou DG, Goldstein I, Quist WC. Preexisting vascular pathology in donor and recipient vessels during penile microvascular arterial bypass surgery. J Urol. 1994 May;151(5):1217-24. 
  94. Pescatori ES, Hatzichristou DG, Namburi S, Goldstein I. A positive intracavernous injection test implies normal veno-occlusive but not necessarily normal arterial function: a hemodynamic study. J Urol. 1994 May;151(5):1209-16.
  95. Chiu AW, Azadzoi KM, Hatzichristou DG, Siroky MB, Krane RJ, Babayan RK. Effects of intra-abdominal pressure on renal tissue perfusion during laparoscopy. J Endourol. 1994 Apr;8(2):99-103.
  96. Kaufman JM, Hatzichristou DG, Mulhall JP, Fitch WP, Goldstein I. Impotence and chronic renal failure: a study of the hemodynamic pathophysiology. J Urol. 1994 Mar;151(3):612-8.
  97. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994 Jan;151(1):54-61.
  98. Goldstein I, Hatzichristou DG. Preface to the special issue on Neurogenic Impotence. Sexuality and Disability, 12: 3-4, 1994.
  99. Hatzichristou DG, Bertero E, Goldstein I. Decision making in the evaluation of impotence: The patient's profile-oriented algorithm. Sexuality and Disability, 12: 29-37, 1994.
  100. Hatzichristou DG, Goldstein I, Kasznica J, Quist W. The native venous architecture is preserved in an arterialized deep dorsal vein graft for arteriogenic impotence: a case report. J Urol. 1993 Apr;149(4):851-5.
  101. Hatzichristou DG, Goldstein I. Penile microvascular arterial bypass: Indications and surgical considerations. Surgery Annual, 27(2):207-229, 1993.
  102. Hatzichristou DG, Goldstein I. Penile microvascular arterial bypass surgery. Atlas Urologic Clinics of North America, 1(1): 39-60, 1993.
  103. Hatzichristou DG, Goldstein I. Arterial bypass surgery for impotence. Current Opinion in Urology, 1(2):144-148, 1991.
     

Δημήτρης Χατζηχρήστου / Χειρουργός Ουρολόγος-Ανδρολόγος / Καθηγητής Ιατρικής Σχολής Α.Π.Θ.
Μητροπόλεως 77, 54622 Θεσσαλονίκη, τηλέφωνο 2310 273177